Testosterone therapy does not up prostate cancer incidence

Testosterone therapy does not up prostate cancer incidence
Testosterone replacement therapy appears to be safe and does not increase the incidence of prostate cancer, according to a study published online June 6 in The Journal of Sexual Medicine.

(HealthDay) -- Testosterone replacement therapy (TRT) appears to be safe and does not increase the incidence of prostate cancer, according to a study published online June 6 in The Journal of Sexual Medicine.

Mark R. Feneley, M.D., from University College Hospital, and Malcolm Carruthers, M.D., from the Centre for Men's Health -- both in London, conducted an updated audit to analyze the long-term incidence of for men receiving TRT. Data were reviewed from 1,365 men (mean age, 55 years) with symptomatic androgen deficiency receiving TRT (pellet , Restandol, mesterolone, and Testogel) and monitored for up to 20 years. All patients were prescreened for prostate cancer, and endocrine, biochemical, hematological, and urinary profiles were conducted at baseline and every six months.

After 2,966 man-years of treatment, the researchers found that 14 new cases of prostate cancer were diagnosed (one case per 212 years of treatment). The mean time to diagnosis was 6.3 years (range, one to 12 years). All of the tumors were suitable for potentially and were clinically localized. Starting treatment had no statistically significant impact on total prostate-specific antigen (PSA), free PSA, or the ratio of free:total PSA. There was no association seen between any initial PSA change and subsequent diagnosis of cancer.

"This study adds to the considerable weight of evidence that with proper clinical monitoring, testosterone treatment is safe for the prostate and improves early detection of prostate cancer," the authors write. "Testosterone treatment with regular monitoring of the prostate may be safer for the individual than any alternative without surveillance."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Testosterone deficiency and replacement therapy in men

Jul 19, 2011

Testosterone deficiency (TD), often referred to as hypogonadism, is associated with aging and affects approximately 30 percent of men ages 40-79. To highlight some of the challenges and controversies encountered in diagnosis ...

New prostate cancer test gives more accurate diagnosis

Apr 06, 2011

In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer -- particularly the aggressive form of the disease -- and substantially reduced false ...

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.